Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Terapia CAR-T In VIVO para Neoplasias Hematológicas Recurrentes/Refractarias

2 de noviembre de 2026 actualizado por: Chongqing Precision Biotech Co., Ltd

In Vivo-Generated Chimeric Antigen Receptor T-Cell Therapy for the Treatment of Relapsed or Refractory Hematologic Malignancies

This study is an investigator-initiated single center, single arm clinical study with a target population of patients with relapsed or refractory malignant hematological tumors.

It is an early exploratory clinical study of the safety, tolerability and initial efficacy in the treatment of relapsed or refractory malignant hematological tumors.

Descripción general del estudio

Descripción detallada

This is an open-label, single-arm study to evaluate the efficacy and safety of in vivo Chimeric Antigen Receptor T-Cell(CAR-T cell) therapy in patients with relapsed refractory malignant hematological tumors. Upon enrollment, subjects will receive an intravenous infusion of the in Vivo CAR-T preparation. Following the infusion, subjects will be hospitalized for observation, and subjects will be evaluated for safety and efficacy. Subjects will be followed for up to 2 years to determine if the disease is under control.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

24

Fase

  • Fase 1

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

  • Nombre: Wang Sanbin, PhD
  • Número de teléfono: +86 13187424131
  • Correo electrónico: sanbin1011@163.com

Ubicaciones de estudio

    • Yunnan
      • Kunming, Yunnan, Porcelana
        • Reclutamiento
        • 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
        • Contacto:
          • Wang Sanbin, PhD
          • Número de teléfono: +86 13187424131
          • Correo electrónico: sanbin1011@163.com
        • Contacto:
          • Sanbin

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  1. Age ≥ 18 years old, gender unrestricted;

  2. Confirmed diagnosis of relapsed/refractory malignant hematological tumors, including B-ALL, B-cell lymphoma and multiple myeloma;

  3. ECOG performance status score 0-2, with an expected survival period of ≥ 3 months;

  4. Blood routine test results during the screening period meet the following criteria:

    ① Hemoglobin ≥ 6 g/dL (no red blood cell transfusion within 1 week before screening), recombinant human erythropoietin (rhEPO) is allowed; for patients meeting the hemoglobin ≥ 6 g/dL criterion, red blood cell transfusion can be used to maintain hemoglobin ≥ 6 g/dL;

    • Absolute neutrophil count (ANC) ≥ 600/μL (no use of granulocyte colony-stimulating factor [G-CSF] within 1 week before screening, or no use of pegylated G-CSF within 2 weeks before screening); ③ Platelet count ≥ 50,000/μL; ④ Lymphocyte count ≥ 500/μL;
  5. Normal renal function during the screening period: creatinine clearance rate (CrCl) ≥ 45 mL/min (calculated using the Cockcroft-Gault formula);

  6. Liver function during the screening period meets the following criteria:

    ① Alanine aminotransferase (ALT), aspartate aminotransferase (AST) ≤ 3.0 × ULN;

    ② Total bilirubin (TBIL) ≤ 2.0 × ULN (except for congenital hyperbilirubinemia such as Gilbert's syndrome, direct bilirubin can be relaxed to ≤ 1.5 × ULN);

  7. Cardiac function during the screening period meets the following criteria:

    ① Left ventricular ejection fraction (LVEF) ≥ 40% (measured by echocardiography or MUGA scan);

    ② No clinically significant pericardial effusion;

    ③ No clinically significant electrocardiogram (ECG) abnormalities;

  8. Pulmonary function during the screening period meets the following criteria: blood oxygen saturation (SpO₂) ≥ 90%;

  9. Women of childbearing age must have a negative pregnancy test during the screening period and before drug administration, and must not be in the lactation period;

  10. Men and women of childbearing age must agree to take effective contraceptive measures and not donate reproductive cells (including sperm or eggs) from the time of signing the informed consent form until 1 year after the end of study drug administration;

  11. The subject or their legally authorized representative has signed the informed consent form (ICF), indicating their understanding of the purpose and procedures of the study and their voluntary participation in this study.

Exclusion Criteria:

  1. Other anti-tumor treatments within the screening period (judged by the investigator comprehensively):

    ① Received chemotherapy, targeted therapy or immunotherapy within 5 half-lives before administration;

    ② Received radiotherapy within 4 weeks before administration (if the radiotherapy target area covers ≤ 5% of bone marrow reserve, the time limit for radiotherapy completion is not restricted);

  2. History of hematopoietic stem cell transplantation: Received allogeneic or autologous hematopoietic stem cell transplantation within 3 months before administration;

  3. History of other malignant tumors (except for this disease), except for the following situations:

    ① Received radical treatment and had no known active disease for ≥ 2 years before enrollment;

    ② Had fully treated non-melanoma skin cancer in the past and had no active lesions at present;

  4. Received treatment related to vesicular stomatitis virus glycoprotein (VSVG) pseudotyped virus in the past;

  5. Had severe and uncontrolled infections (bacterial, viral, fungal, etc.) within the screening period;

  6. Clinically significant cardiac diseases:

    • Had symptomatic heart failure or other serious cardiac diseases (such as severe arrhythmia);

      • Had New York Heart Association (NYHA) Class III-IV congestive heart failure; ③ Had a myocardial infarction or received coronary artery bypass grafting (CABG) / coronary artery stent implantation within 6 months before signing the informed consent;

        • Had clinically significant ventricular arrhythmia or a history of unexplained syncope; ⑤ Had a history of syncope (excluding cases caused by vasovagal reactions or dehydration); ⑥ Had a history of severe non-ischemic cardiomyopathy;
  7. Other clinically significant diseases, including but not limited to:

    • Primary immunodeficiency; ② Had a stroke or seizure within 6 months before screening;

      • Had clear clinical evidence of dementia or mental status changes; ④ Had Parkinson's disease, Parkinson-like movement disorders or a history of the above;
  8. Had undergone surgery within 2 weeks before administration, or planned to undergo surgery within 2 weeks after administration (local anesthesia surgery excluded);

  9. Had received live attenuated vaccines within 1 month before administration;

  10. Had a history of severe allergic reactions to this product or its formulation components;

  11. Patients who were not suitable for establishing intravenous access;

  12. The investigator believed that there were other conditions that made the patient unsuitable for participating in this study.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: N / A
  • Modelo Intervencionista: Asignación de un solo grupo
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: CAR-T in vivo

Patients were enrolled and given a single dose of CAR-T injection intravenously, hospitalized for observation over the following month, and followed up for observation over the following 2 years.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Maximal Tolerated Dose(MTD)
Periodo de tiempo: Up to 28 days after infusion

MTD will be determined based on Dose-Limiting Toxicity(DLTs) observed during the first 28 days of study treatment.

Up to 28 days after infusion
Incidence of adverse events(AE) after infusion
Periodo de tiempo: Up to 28 days after infusion

The frequency, severity, and laboratory findings of all adverse events/serious adverse events are included.

Up to 28 days after infusion

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Objective Response Rate
Periodo de tiempo: Day 28、Month 2、Month 3、Month 6、Month 12、Month 18、Month 24

Objective Response Rate(ORR) is defined as the proportion of subjects achieving complete remission(CR) and partial response(PR).

Day 28、Month 2、Month 3、Month 6、Month 12、Month 18、Month 24

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Investigadores

  • Investigador principal: Wang Sanbin, MD, 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

1 de julio de 2025

Finalización primaria (Estimado)

31 de diciembre de 2027

Finalización del estudio (Estimado)

31 de diciembre de 2028

Fechas de registro del estudio

Enviado por primera vez

16 de noviembre de 2025

Primero enviado que cumplió con los criterios de control de calidad

16 de noviembre de 2025

Publicado por primera vez (Actual)

20 de noviembre de 2025

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

4 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

2 de noviembre de 2026

Última verificación

1 de noviembre de 2025

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir